Comparison Study of the Bio-Plex and Meso Scale Multiplexed SARS-CoV-2 Serology Assays Reveals Evidence of Diminished Host Antibody Responses to SARS-CoV-2 after Monoclonal Antibody Treatment
Article Sidebar
Main Article Content
Abstract
Background: Assessing the breadth and duration of antigen-specific binding antibodies provides valuable information for evaluating interventions to treat or prevent SARS-CoV-2 infection. Multiplex immunoassays are a convenient method for rapid measurement of antibody responses but can sometimes provide discordant results, and antibody positive percent agreement for COVID-19 diagnosis can vary depending on assay type, disease severity, and population sampled. Therefore, we compared two assays marked for research applications, MSD and Bio-Plex Pro, to evaluate qualitative interpretation of serostatus and quantitative detection of antibodies of varying isotypes (IgG, IgM, and IgA) against receptor binding domain (RBD) and nucleocapsid (N) antigens.
Methods: Specimens from ACTIV-2/A5401, a placebo-controlled clinical trial of the SARS-CoV-2 monoclonal antibody (mAb) bamlanivimab to prevent COVID-19 disease progression, were used to evaluate the concordance of the Bio-Rad Bio-Plex Pro Human SARS-CoV-2 Serology Assay and the Meso Scale Discovery (MSD) V-PLEX COVID-19 Panel 1 serology assay in detecting and quantifying IgG, IgA, and IgM binding anti-SARS-CoV-2 antibody responses against the RBD and N antigens. Data were disaggregated by study arm, bamlanivimab dose, days post-enrollment, and presence of emerging resistance.
Results: We observed 90.5% (412 of 455 tests) concordance for anti-RBD IgG and 87% (396 of 455) concordance for anti-N IgG in classifying samples as negative or positive based on assay-defined cutoffs. Antibody levels converted to the WHO standard BAU/mL were significantly correlated for all isotypes (IgG, IgM, and IgA) and SARS-CoV-2 antigen targets (RBD and N) tested that were common between the two assays (Spearman r 0.65 to 0.92, P < 0.0001). Both assays uncovered evidence of diminished host-derived IgG immune responses in participants treated with bamlanivimab compared to placebo. Assessment of immune responses in the four individuals treated with the 700 mg of bamlanivimab with emerging mAb resistance demonstrated a stronger anti-N IgG response (MSD) at day 28 (median 2.18 log BAU/mL) compared to participants treated with bamlanivimab who did not develop resistance (median 1.55 log BAU/mL).
Conclusions: These data demonstrate the utility in using multiplex immunoassays for characterizing the immune responses with and without treatment in a study population and provide evidence that monoclonal antibody treatment in acute COVID-19 may have a modest negative impact on development of host IgG responses.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Marra AR, Kobayashi T, Suzuki H, Alsuhaibani M, Tofaneto BM, Bariani LM, Auler MA, Salinas JL, Edmond MB, Doll M, Kutner JM, Pinho JRR, Rizzo LV, Miraglia JL, Schweizer ML. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis. J Infect. 2022;84(3):297-310. doi: 10.1016/j.jinf.2021.12.035. PubMed PMID: 34982962; PMCID: PMC8720049.
2. Zhou Y, Zhang L, Xie YH, Wu J. Advancements in detection of SARS-CoV-2 infection for confronting COVID-19 pandemics. Lab Invest. 2022;102(1):4-13. doi: 10.1038/s41374-021-00663-w. PubMed PMID: 34497366; PMCID: PMC8424153.
3. Moser C, Li JZ, Eron JJ, Aga E, Daar ES, Wohl DA, Coombs RW, Javan AC, Bender Ignacio RA, Jagannathan P, Ritz J, Sieg SF, Parikh UM, Hughes MD, Currier JS, Smith DM, Chew KW, Team A-AS. Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19. Open Forum Infect Dis. 2022;9(11):ofac618. doi: 10.1093/ofid/ofac618. PubMed PMID: 36467293; PMCID: PMC9709705.
4. Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G, Hettiarachchi D, Mathangasinghe Y, Weeratunga P, Wickramasinghe D, Bergman H, Buckley BS, Probyn K, Sguassero Y, Davenport C, Cunningham J, Dittrich S, Emperador D, Hooft L, Leeflang MM, McInnes MD, Spijker R, Struyf T, Van den Bruel A, Verbakel JY, Takwoingi Y, Taylor-Phillips S, Deeks JJ, Cochrane C-DTAG. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2022;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. PubMed PMID: 36394900; PMCID: PMC9671206.
5. Kenny G, Negi R, O’Reilly S, Garcia-Leon A, Alalwan D, Gaillard CM, Saini G, Inzitari R, Feeney ER, Yousif O, Cotter AG, de Barra E, Sadlier C, Crispie F, Doran P, Gautier V, Mallon PWG, All Ireland Infectious Diseases cohort s. Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination. J Immunol Methods. 2022;510:113345. doi: 10.1016/j.jim.2022.113345. PubMed PMID: 36055441; PMCID: PMC9425705.
6. Meso Scale Discovery. MSD Multi-Spot Assay System COVID-19 Serology Kit V-Plex. Available at: https://www.mesoscale.com/~/media/files/product%20inserts/v-plex%20covid-19%20serology%20assays%20insert.pdf: 2022.
7. Bozorgmehr N, Mashhouri S, Perez Rosero E, Xu L, Shahbaz S, Sligl W, Osman M, Kutsogiannis DJ, MacIntyre E, O’Neil CR, Elahi S. Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection. mBio. 2021;12(3). doi: 10.1128/mBio.00384-21. PubMed PMID: 33947753; PMCID: PMC8262904.
8. Bolton JS, Chaudhury S, Dutta S, Gregory S, Locke E, Pierson T, Bergmann-Leitner ES. Comparison of ELISA with electro-chemiluminescence technology for the qualitative and quantitative assessment of serological responses to vaccination. Malar J. 2020;19(1):159. doi: 10.1186/s12936-020-03225-5. PubMed PMID: 32303235; PMCID: PMC7165447.
9. Blom K, Marking U, Havervall S, Norin NG, Gordon M, Garcia M, Tecleab T, Christ W, Forsell M, Phillipson M, Nilsson P, Mangsbo S, Hober S, Aberg M, Klingstrom J, Thalin C. Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection. Lancet Infect Dis. 2022;22(7):943-5. doi: 10.1016/S1473-3099(22)00362-0. PubMed PMID: 35691303; PMCID: PMC9183210.
10. Yang F, Nielsen SCA, Hoh RA, Roltgen K, Wirz OF, Haraguchi E, Jean GH, Lee JY, Pham TD, Jackson KJL, Roskin KM, Liu Y, Nguyen K, Ohgami RS, Osborne EM, Nadeau KC, Niemann CU, Parsonnet J, Boyd SD. Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues. Science. 2021;372(6543):738-41. doi: 10.1126/science.abf6648. PubMed PMID: 33846272; PMCID: PMC8139427.
11. Jacob-Dolan C, Feldman J, McMahan K, Yu J, Zahn R, Wegmann F, Schuitemaker H, Schmidt AG, Barouch DH. Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection. J Virol. 2021;95(11). doi: 10.1128/JVI.00117-21. PubMed PMID: 33692201; PMCID: PMC8139699.
12. Alter G, Yu J, Liu J, Chandrashekar A, Borducchi EN, Tostanoski LH, McMahan K, Jacob-Dolan C, Martinez DR, Chang A, Anioke T, Lifton M, Nkolola J, Stephenson KE, Atyeo C, Shin S, Fields P, Kaplan I, Robins H, Amanat F, Krammer F, Baric RS, Le Gars M, Sadoff J, de Groot AM, Heerwegh D, Struyf F, Douoguih M, van Hoof J, Schuitemaker H, Barouch DH. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021;596(7871):268-72. doi: 10.1038/s41586-021-03681-2. PubMed PMID: 34107529; PMCID: PMC8357629.
13. Grunau B, Asamoah-Boaheng M, Lavoie PM, Karim ME, Kirkham TL, Demers PA, Barakauskas V, Marquez AC, Jassem AN, O’Brien SF, Drews SJ, Haig S, Cheskes S, Goldfarb DM. A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval. Clin Infect Dis. 2022;75(1):e888-e91. doi: 10.1093/cid/ciab938. PubMed PMID: 34849655; PMCID: PMC8690265.
14. Woldemeskel BA, Garliss CC, Aytenfisu TY, Johnston TS, Beck EJ, Dykema AG, Frumento N, Wright DA, Yang AH, Damanakis AI, Laeyendecker O, Cox AL, Mostafa HH, Karaba AH, Blankson JN. SARS-CoV-2-specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. JCI Insight. 2022;7(10). doi: 10.1172/jci.insight.159474. PubMed PMID: 35389888; PMCID: PMC9220829.
15. Sohaei D, Ulndreaj A, Mathew A, Campbell C, Stengelin M, Sigal G, Joe J, Romero D, Padmanabhan N, Ren A, Ghorbani A, Soosaipillai A, Kulasingam V, Prassas I, Diamandis EP. Sensitive Serology Measurements in the Saliva of Individuals with COVID-19 Symptoms Using a Multiplexed Immunoassay. J Appl Lab Med. 2022;7(6):1354-65. doi: 10.1093/jalm/jfac073. PubMed PMID: 36179121; PMCID: PMC9619505.
16. Karaba AH, Johnston TS, Aytenfisu TY, Akinde O, Eby Y, Ruff JE, Abedon AT, Alejo JL, Blankson JN, Cox AL, Bailey JR, Klein SL, Pekosz A, Segev DL, Tobian AAR, Werbel WA. A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. Transplantation. 2022;106(7):1440-4. doi: 10.1097/TP.0000000000004140. PubMed PMID: 35417115; PMCID: PMC9213052.
17. Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells A, Shurin MR. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol Spectr. 2021;9(1):e0034121. doi: 10.1128/Spectrum.00341-21. PubMed PMID: 34346750; PMCID: PMC8552678.
18. Saraf S, Zhu X, Shrestha R, Bonny TS, Baker OR, Beck EJ, Fernandez RE, Eby Y, Akinde O, Ruff JE, Caturegli P, Redd AD, Bloch EM, Quinn TC, Tobian AAR, Laeyendecker O. Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals. PLoS One. 2022;17(6):e0264298. doi: 10.1371/journal.pone.0264298. PubMed PMID: 35679259; PMCID: PMC9182712.
19. Ige F, Hamada Y, Steinhardt L, Iriemenam NC, Uwandu M, Greby SM, Aniedobe M, Salako BL, Rangaka MX, Abubakar I, Audu R. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population. Microbiol Spectr. 2021;9(2):e0068021. doi: 10.1128/Spectrum.00680-21. PubMed PMID: 34612691; PMCID: PMC8510257.
20. Yun S, Ryu JH, Jang JH, Bae H, Yoo SH, Choi AR, Jo SJ, Lim J, Lee J, Ryu H, Cho SY, Lee DG, Lee J, Kim SC, Park YJ, Lee H, Oh EJ. Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays. Ann Lab Med. 2021;41(6):577-87. doi: 10.3343/alm.2021.41.6.577. PubMed PMID: 34108285; PMCID: PMC8203431.
21. Ong DSY, Fragkou PC, Schweitzer VA, Chemaly RF, Moschopoulos CD, Skevaki C, European Society of Clinical M, Infectious Diseases Study Group for Respiratory V. How to interpret and use COVID-19 serology and immunology tests. Clin Microbiol Infect. 2021;27(7):981-6. doi: 10.1016/j.cmi.2021.05.001. PubMed PMID: 33975005; PMCID: PMC8106522.
22. Ward MD, Mullins KE, Pickett E, Merrill V, Ruiz M, Rebuck H, Duh SH, Christenson RH. Performance of 4 Automated SARS-CoV-2 Serology Assay Platforms in a Large Cohort Including Susceptible COVID-19-Negative and COVID-19-Positive Patients. J Appl Lab Med. 2021;6(4):942-52. doi: 10.1093/jalm/jfab014. PubMed PMID: 33693808; PMCID: PMC7989439.
23. Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs RW, Ritz J, Giganti M, Javan AC, Li Y, Choudhary MC, Deo R, Malvestutto C, Klekotka P, Price K, Nirula A, Fischer W, Bala V, Ribeiro RM, Perelson AS, Fletcher CV, Eron JJ, Currier JS, Team A-AS, Hughes MD, Smith DM. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun. 2022;13(1):4931. doi: 10.1038/s41467-022-32551-2. PubMed PMID: 35995785; PMCID: PMC9395368.
24. Cox C, Gao Q. Quantitative Bio-Plex Pro Human IgG SARS-CoV-2 Serology Assays Using a Standard Curve. Bio-Rad Laboratories Technical Bulletin 3208 Ver A. Available online at https://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_3208.pdf.2021 8/20/2021.
25. Bio-Rad. Bio-Plex Pro Human IgA and IgM SARS-CoV-2 Serology Assays Protocol. Bulletin 3224. https://www.bio-rad.com/sites/default/files/2021-08/Bulletin_3224.pdf: Bio-Rad Laboratories; 2021 [cited 2022 February 2].
26. Infantino M, Pieri M, Nuccetelli M, Grossi V, Lari B, Tomassetti F, Calugi G, Pancani S, Benucci M, Casprini P, Manfredi M, Bernardini S. The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays. Int Immunopharmacol. 2021;100:108095. doi: 10.1016/j.intimp.2021.108095. PubMed PMID: 34619529; PMCID: PMC8403673.
27. Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackbourne JL, Heinz BA, Foster D, Higgs RE, Balasubramaniam D, Wang L, Zhang Y, Yang ES, Bidshahri R, Kraft L, Hwang Y, Zentelis S, Jepson KR, Goya R, Smith MA, Collins DW, Hinshaw SJ, Tycho SA, Pellacani D, Xiang P, Muthuraman K, Sobhanifar S, Piper MH, Triana FJ, Hendle J, Pustilnik A, Adams AC, Berens SJ, Baric RS, Martinez DR, Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli HM, de Vries M, Mohamed A, Dittmann M, Samanovic MI, Mulligan MJ, Goldsmith JA, Hsieh CL, Johnson NV, Wrapp D, McLellan JS, Barnhart BC, Graham BS, Mascola JR, Hansen CL, Falconer E. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021;13(593). doi: 10.1126/scitranslmed.abf1906. PubMed PMID: 33820835; PMCID: PMC8284311.
28. Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, Moser C, Hughes MD, Ritz J, Ribeiro RM, Ke R, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Fletcher CV, Daar ES, Wohl DA, Eron JJ, Currier JS, Parikh UM, Sieg SF, Perelson AS, Coombs RW, Smith DM, Li JZ, Team A-AS. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat Microbiol. 2022;7(11):1906-17. doi: 10.1038/s41564-022-01254-1. PubMed PMID: 36289399.
29. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, Mills R, Teng E, Kamruzzaman M, Garcia-Beltran WF, Astudillo M, Yang D, Miller TE, Oliver E, Fischinger S, Atyeo C, Iafrate AJ, Calderwood SB, Lauer SA, Yu J, Li Z, Feldman J, Hauser BM, Caradonna TM, Branda JA, Turbett SE, LaRocque RC, Mellon G, Barouch DH, Schmidt AG, Azman AS, Alter G, Ryan ET, Harris JB, Charles RC. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52). doi: 10.1126/sciimmunol.abe0367. PubMed PMID: 33033172; PMCID: PMC7857394.
30. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73-82. doi: 10.1038/s41577-020-00480-0. PubMed PMID: 33340022; PMCID: PMC7747004.
31. Zhang L, Poorbaugh J, Dougan M, Chen P, Gottlieb RL, Huhn G, Beasley S, Daniels M, Ngoc Vy Trinh T, Crisp M, Freitas JJ, Vaillancourt P, Patel DR, Nirula A, Kallewaard NL, Higgs RE, Benschop RJ. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together. Front Immunol. 2021;12:790469. doi: 10.3389/fimmu.2021.790469. PubMed PMID: 34956222; PMCID: PMC8697104.
32. Kweon OJ, Lim YK, Kim HR, Kim MC, Choi SH, Chung JW, Lee MK. Antibody kinetics and serologic profiles of SARS-CoV-2 infection using two serologic assays. PLoS One. 2020;15(10):e0240395. doi: 10.1371/journal.pone.0240395. PubMed PMID: 33091042; PMCID: PMC7580996.
33. Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, Guivel-Benhassine F, Staropoli I, Chazal M, Dufloo J, Planas D, Buchrieser J, Rajah MM, Robinot R, Porrot F, Albert M, Chen KY, Crescenzo-Chaigne B, Donati F, Anna F, Souque P, Gransagne M, Bellalou J, Nowakowski M, Backovic M, Bouadma L, Le Fevre L, Le Hingrat Q, Descamps D, Pourbaix A, Laouenan C, Ghosn J, Yazdanpanah Y, Besombes C, Jolly N, Pellerin-Fernandes S, Cheny O, Ungeheuer MN, Mellon G, Morel P, Rolland S, Rey FA, Behillil S, Enouf V, Lemaitre A, Creach MA, Petres S, Escriou N, Charneau P, Fontanet A, Hoen B, Bruel T, Eloit M, Mouquet H, Schwartz O, van der Werf S. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020;12(559). doi: 10.1126/scitranslmed.abc3103. PubMed PMID: 32817357; PMCID: PMC7665313.